<DOC>
	<DOCNO>NCT02335983</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability activity once-weekly regimen carfilzomib combination lenalidomide dexamethasone treatment multiple myeloma .</brief_summary>
	<brief_title>Phase 1b Study Carfilzomib Administered Once Weekly Combination With Lenalidomide Dexamethasone Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key 1 . Newly diagnose relapse multiple myeloma 2 . Measureable disease Serum M protein , Urine M protein , serum free light chain ( SFLC ) abnormal serum kappa lambda ratio ( subject without detectable serum urine Mprotein ) , Serum quantitative immunoglobulin A ( qlgA ) ( immunoglobulin ( Ig ) A subject whose disease reliable measure qlgA ) . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 4 . Left ventricular ejection fraction ( LVEF ) ≥ 40 % Key 1 . Waldenström macroglobulinemia 2 . For newly diagnose multiple myeloma : multiple myeloma IgM subtype 3 . For relapsed disease : 1 . If treat lenalidomide dexamethasone combination , progression first 3 month initiate treatment . 2 . Any progression treatment lenalidomide dexamethasone regimen recent line therapy . 3 . Any prior treatment carfilzomib 4 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 5 . Plasma cell leukemia ( &gt; 2.0 × 10^9/L circulate plasma cell standard differential ) 6 . Myelodysplastic syndrome 7 . Amyloidosis 8 . Prior treatment carfilzomib oprozomib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>